Heck Capital Advisors LLC Sells 5,162 Shares of Johnson & Johnson (NYSE:JNJ)

Heck Capital Advisors LLC trimmed its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 67.4% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 2,499 shares of the company's stock after selling 5,162 shares during the period. Heck Capital Advisors LLC's holdings in Johnson & Johnson were worth $414,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. William B. Walkup & Associates Inc. boosted its position in shares of Johnson & Johnson by 4.7% in the 1st quarter. William B. Walkup & Associates Inc. now owns 12,674 shares of the company's stock worth $2,102,000 after purchasing an additional 574 shares during the last quarter. E Fund Management Co. Ltd. boosted its position in shares of Johnson & Johnson by 15.6% in the 1st quarter. E Fund Management Co. Ltd. now owns 32,801 shares of the company's stock worth $5,440,000 after purchasing an additional 4,425 shares during the last quarter. Financial Network Wealth Advisors LLC boosted its position in shares of Johnson & Johnson by 60.5% in the 1st quarter. Financial Network Wealth Advisors LLC now owns 1,194 shares of the company's stock worth $198,000 after purchasing an additional 450 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Johnson & Johnson by 7.0% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock worth $12,164,000 after purchasing an additional 4,816 shares during the last quarter. Finally, Triglav Skladi D.O.O. boosted its position in shares of Johnson & Johnson by 5.0% in the 1st quarter. Triglav Skladi D.O.O. now owns 62,500 shares of the company's stock worth $10,365,000 after purchasing an additional 3,000 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

JNJ opened at $172.79 on Wednesday. The business's 50-day moving average price is $160.00 and its two-hundred day moving average price is $157.90. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $174.76. The company has a market capitalization of $416.14 billion, a price-to-earnings ratio of 18.48, a P/E/G ratio of 2.21 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.82 earnings per share. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. Johnson & Johnson's payout ratio is currently 55.61%.

Analysts Set New Price Targets

Several research firms have recently issued reports on JNJ. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Barclays raised their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus target price of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.